UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/053,329	11/09/2001	Michael Baudino	11738.00050	4048	
27581 MEDTRONIC	27581 7590 08/02/2007 MEDTRONIC, INC.			EXAMINER	
710 MEDTRONIC PARKWAY NE			WITCZAK, CATHERINE		
MINNEAPOL	IS, MN 55432-9924		ART UNIT	PAPER NUMBER .	
•	•		3767		
				DELUCENTATOR	
			MAIL DATE	DELIVERY MODE	
			08/02/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

		Ł					
	Application No.	Applicant(s)					
	10/053,329	BAUDINO ET AL.					
Office Action Summary	Examiner	Art Unit					
	Catherine N. Witczak	3767					
The MAILING DATE of this communication a Period for Reply	ppears on the cover sheet with the o	correspondence address					
A SHORTENED STATUTORY PERIOD FOR REP WHICHEVER IS LONGER, FROM THE MAILING - Extensions of time may be available under the provisions of 37 CFR 1 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory perior Failure to reply within the set or extended period for reply will, by state Any reply received by the Office later than three months after the mail earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNICATION 1.136(a). In no event, however, may a reply be tired will apply and will expire SIX (6) MONTHS from the, cause the application to become ABANDONE	N. nely filed the mailing date of this communication. ED (35 U.S.C.§ 133).					
Status							
1)⊠ Responsive to communication(s) filed on 14	<u>June 2007</u> .						
2a)⊠ This action is FINAL . 2b)☐ Th	This action is FINAL . 2b) ☐ This action is non-final.						
3) Since this application is in condition for allow	☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
closed in accordance with the practice under	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims							
4)⊠ Claim(s) <u>1-80,82-86,89-107 and 110-141</u> is/are pending in the application.							
4a) Of the above claim(s). 1-79 and 110-141	4a) Of the above claim(s) 1-79 and 110-141 is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.							
6)⊠ Claim(s) 80, 82-86 and 89-107 is/are rejecte	6)⊠ Claim(s) <u>80, 82-86 and 89-107</u> is/are rejected.						
7) Claim(s) is/are objected to.	7) Claim(s) is/are objected to.						
8) Claim(s) are subject to restriction and	or election requirement.						
Application Papers							
9) The specification is objected to by the Examin	ner.						
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).							
11) ☐ The oath or declaration is objected to by the	Examiner. Note the attached Office	Action or form PTO-152.					
Priority under 35 U.S.C. § 119							
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority docume 2. Certified copies of the priority docume 3. Copies of the certified copies of the priority docume application from the International Bure * See the attached detailed Office action for a list	nts have been received. nts have been received in Applicat iority documents have been receive au (PCT Rule 17.2(a)).	ion No ed in this National Stage					
Attachment(s)							
1) Notice of References Cited (PTO-892)	4)						
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	5) Notice of Informal F						

Part of Paper No./Mail Date 20070729 WWW 1/2107

DETAILED ACTION

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- 1. Claims 80, 82, 83, 85, 86, 89, 103, 106 and 107 are rejected under 35 U.S.C. 102(b) as being anticipated by Edwards et al (US 5,588,960).

Edwards et al disclose in Figures 1 and 2 a delivery system comprising a cannula (22) having a distal end with a plurality of openings (28) having a curved passageways (56b) capable of directing a catheter (241) outwardly along a distinct trajectory; and a replenishment port (96).

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

- (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 2. Claims 84, 90, 91, 92, 93, 95, 96, 97, 98, 99, 100, 101, 102, 104, and 105 are rejected under 35 U.S.C. 103(a) as being unpatentable over Edwards et al in view of Cosgrove, Jr. et al. (US 4,533,346).

Edwards et al disclose the claimed invention except for reading a parameter and level of signal to control liquid infusion rate, adjusting rate, and exceeding a maximum setting value results in indicative



Art Unit: 3767

output. Cosgrove discloses a interfaced control scheme used in the prior art that adjusts a setting of

infusion rates based on, multiple analog signal levels based on the drug or physiological parameters (col.

3, line 55 - col. 5, line 62). It would have been obvious to one of ordinary skill in the art at the time of the

invention to use the teachings of Cosgrove in the system of Edwards et al in order to achieve precise

control of drug delivery to a patient. It would have been obvious to one of ordinary skill in the art at the

time of the invention to use alarms and telemetry in the process control scheme in order to alert the user

when maximum or dangerous levels are exceeded to provide a better level of control and to use telemetry

to enable remote control settings to be established.

3. Claim 94 is rejected under 35 U.S.C. 103(a) as being unpatentable over Edwards et al as modified

by Cosgrove, Jr. et al in further view of Abbott et al (US Re. 36386).

Edwards et al as modified by Cosgrove disclose the claimed invention except for resetting a timer

when a parameter is changed. Abbott teaches resetting a timer when a parameter associated the flowrate is

changed. (see paragraph (d) of claim 31). It would have been obvious to one of ordinary skill in the art at

the time of the invention to use the teachings of Abbott in the system of Edwards et al in view of

Cosgrove in order to obtain additional flow information concerning drug delivery parameters to more

precisely control the drug delivery profile to the patient.

Response to Arguments

Applicant's arguments with respect to claims 80, 82-86, and 89-107 have been considered but are

moot in view of the new ground(s) of rejection.

W

Art Unit: 3767

Conclusion

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Catherine N. Witczak whose telephone number is (571) 272-7179. The examiner can normally be reached on Monday through Friday, 8-5 EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Kevin Sirmons can be reached on (571) 272-4965. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/053,329

Art Unit: 3767

Page 5

Information regarding the status of an application may be obtained from the Patent Application

Information Retrieval (PAIR) system. Status information for published applications may be obtained

from either Private PAIR or Public PAIR. Status information for unpublished applications is available

through Private PAIR only. For more information about the PAIR system, see http://pair-

direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic

Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer

Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR

CANADA) or 571-272-1000.

mm 1/4/07

KEVIN C. SIRMONS SUPERVIȘORY PATENT EXAMINER

Mevir C. kromons